Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 3.03
ACRX's Cash to Debt is ranked higher than
72% of the 509 Companies
in the Global Medical Devices industry.

( Industry Median: 2.15 vs. ACRX: 3.03 )
ACRX' s 10-Year Cash to Debt Range
Min: 0.31   Max: 7.22
Current: 3.03

0.31
7.22
Equity to Asset 0.54
ACRX's Equity to Asset is ranked higher than
61% of the 472 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ACRX: 0.54 )
ACRX' s 10-Year Equity to Asset Range
Min: 0.43   Max: 0.67
Current: 0.54

0.43
0.67
F-Score: 2
Z-Score: -0.12
M-Score: -4.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -721.66
ACRX's Operating margin (%) is ranked lower than
55% of the 485 Companies
in the Global Medical Devices industry.

( Industry Median: 4.94 vs. ACRX: -721.66 )
ACRX' s 10-Year Operating margin (%) Range
Min: -1805.22   Max: -22.6
Current: -721.66

-1805.22
-22.6
Net-margin (%) -639.31
ACRX's Net-margin (%) is ranked lower than
55% of the 485 Companies
in the Global Medical Devices industry.

( Industry Median: 2.98 vs. ACRX: -639.31 )
ACRX' s 10-Year Net-margin (%) Range
Min: -1875.09   Max: -79.4
Current: -639.31

-1875.09
-79.4
ROE (%) -55.68
ACRX's ROE (%) is ranked higher than
52% of the 476 Companies
in the Global Medical Devices industry.

( Industry Median: 3.46 vs. ACRX: -55.68 )
ACRX' s 10-Year ROE (%) Range
Min: -130.03   Max: -43.78
Current: -55.68

-130.03
-43.78
ROA (%) -33.78
ACRX's ROA (%) is ranked higher than
56% of the 512 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. ACRX: -33.78 )
ACRX' s 10-Year ROA (%) Range
Min: -134.55   Max: -26.84
Current: -33.78

-134.55
-26.84
ROC (Joel Greenblatt) (%) -502.74
ACRX's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 509 Companies
in the Global Medical Devices industry.

( Industry Median: 5.54 vs. ACRX: -502.74 )
ACRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2973.59   Max: -173.98
Current: -502.74

-2973.59
-173.98
Revenue Growth (3Y)(%) 26.00
ACRX's Revenue Growth (3Y)(%) is ranked higher than
98% of the 342 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. ACRX: 26.00 )
ACRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 26
Current: 26

0
26
EBITDA Growth (3Y)(%) -12.50
ACRX's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. ACRX: -12.50 )
ACRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -12.5
Current: -12.5

EPS Growth (3Y)(%) -12.80
ACRX's EPS Growth (3Y)(%) is ranked higher than
68% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: -2.00 vs. ACRX: -12.80 )
ACRX' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -12.8
Current: -12.8

» ACRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ACRX Guru Trades in Q1 2014

Louis Moore Bacon 36,000 sh (New)
» More
Q2 2014

ACRX Guru Trades in Q2 2014

Louis Moore Bacon 50,000 sh (+38.89%)
» More
Q3 2014

ACRX Guru Trades in Q3 2014

Paul Tudor Jones 11,400 sh (New)
Louis Moore Bacon Sold Out
» More
Q4 2014

ACRX Guru Trades in Q4 2014

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ACRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.10
ACRX's P/B is ranked higher than
60% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. ACRX: 4.10 )
ACRX' s 10-Year P/B Range
Min: 2.16   Max: 78
Current: 4.1

2.16
78
P/S 36.80
ACRX's P/S is ranked lower than
75% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 4.16 vs. ACRX: 36.80 )
ACRX' s 10-Year P/S Range
Min: 7.21   Max: 163
Current: 36.8

7.21
163
EV-to-EBIT -4.01
ACRX's EV-to-EBIT is ranked higher than
52% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 151.63 vs. ACRX: -4.01 )
ACRX' s 10-Year EV-to-EBIT Range
Min: -99.2   Max: -1.1
Current: -4.01

-99.2
-1.1
Current Ratio 5.56
ACRX's Current Ratio is ranked higher than
88% of the 508 Companies
in the Global Medical Devices industry.

( Industry Median: 2.58 vs. ACRX: 5.56 )
ACRX' s 10-Year Current Ratio Range
Min: 0.43   Max: 15.22
Current: 5.56

0.43
15.22
Quick Ratio 5.56
ACRX's Quick Ratio is ranked higher than
90% of the 508 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. ACRX: 5.56 )
ACRX' s 10-Year Quick Ratio Range
Min: 0.43   Max: 15.22
Current: 5.56

0.43
15.22

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.40
ACRX's Price/Net Cash is ranked higher than
95% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ACRX: 5.40 )
ACRX' s 10-Year Price/Net Cash Range
Min: 3.05   Max: 8.31
Current: 5.4

3.05
8.31
Price/Net Current Asset Value 5.40
ACRX's Price/Net Current Asset Value is ranked higher than
92% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ACRX: 5.40 )
ACRX' s 10-Year Price/Net Current Asset Value Range
Min: 2.53   Max: 8.01
Current: 5.4

2.53
8.01
Price/Tangible Book 4.10
ACRX's Price/Tangible Book is ranked higher than
75% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 8.20 vs. ACRX: 4.10 )
ACRX' s 10-Year Price/Tangible Book Range
Min: 2.08   Max: 57.94
Current: 4.1

2.08
57.94
Price/Median PS Value 0.80
ACRX's Price/Median PS Value is ranked higher than
85% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 1.30 vs. ACRX: 0.80 )
ACRX' s 10-Year Price/Median PS Value Range
Min: 0.37   Max: 1.26
Current: 0.8

0.37
1.26
Earnings Yield (Greenblatt) -25.80
ACRX's Earnings Yield (Greenblatt) is ranked lower than
59% of the 491 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. ACRX: -25.80 )
ACRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -33.9   Max: 0
Current: -25.8

-33.9
0

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:R5X.Germany,
AcelRx Pharmaceuticals Inc was was incorporated in Delaware on July 13, 2005 as SuRx, Inc. In January 2006, the Company has changed its name to AcelRx Pharmaceuticals, Inc. It is a development stage company. The Company is a specialty pharmaceutical company engaged in the development and commercialization of therapies for the treatment of acute and breakthrough pain. The Company's main product candidate, Zalviso, formerly known as the Sufentanil NanoTab PCA System, or ARX-01, is currently under review by the FDA for marketing approval, and is designed to improve the management of moderate-to-severe acute pain in patients in the hospital setting. In addition, in December 2013, the Company entered into a collaboration agreement with Grünenthal for the commercialization of Zalviso in Europe and Australia. Its sufentanil-based products are subject to extensive regulation by the DEA, due to their status as scheduled drugs. Its registered trademarks include ACELRX and NANOTAB.
» More Articles for ACRX

Headlines

Articles On GuruFocus.com
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against AcelRx Pharmaceutica Oct 15 2014 
Weekly CFO Buys Highlight: BK, MWW, BLD, ACRX, PSEC Sep 12 2011 

More From Other Websites
AcelRx Pharmaceuticals Announces Presentation Of Sublingual Sufentanil Data At The Society of... Apr 14 2015
AcelRx Pharmaceuticals Announces Presentation Of Sublingual Sufentanil Data At The Society of... Apr 14 2015
AcelRx Pharmaceuticals, Inc. Former Employees With Information Concerning Zalviso System Dispensing... Apr 08 2015
ACELRX PHARMACEUTICALS INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Change... Apr 03 2015
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events Mar 23 2015
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Mar 20 2015
AcelRx Appoints Howard B. Rosen as Interim CEO Mar 20 2015
AcelRx Appoints Howard B. Rosen as Interim CEO Mar 20 2015
ACELRX PHARMACEUTICALS INC Financials Mar 19 2015
AcelRx Starts Pivotal Study on Acute Pain Management Drug - Analyst Blog Mar 17 2015
AcelRx Pharmaceuticals Announces Initiation Of Pivotal Phase 3 Trial For ARX-04 Mar 16 2015
AcelRx Pharmaceuticals Announces Initiation Of Pivotal Phase 3 Trial For ARX-04 Mar 16 2015
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000... Mar 13 2015
ACELRX PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 13 2015
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 12 2015
AcelRx Pharmaceuticals (ACRX) Stock Extends Losses Today as Jefferies Downgrades Mar 10 2015
Jefferies Downgrades AcelRx Pharmaceuticals After FDA Requests Additional Clinical Trial For Lead... Mar 10 2015
AcelRx Pharma Meets Expectations, But Says It Won't Submit New Zalviso Application Mar 09 2015
AcelRx Pharmaceuticals reports 4Q loss Mar 09 2015
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results Mar 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK